Modern Chinese Medicine Group Past Earnings Performance
Past criteria checks 2/6
Modern Chinese Medicine Group has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 12.3% per year. Modern Chinese Medicine Group's return on equity is 10.3%, and it has net margins of 14.2%.
Key information
5.9%
Earnings growth rate
-2.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 12.3% |
| Return on equity | 10.3% |
| Net Margin | 14.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Lacklustre Performance Is Driving Modern Chinese Medicine Group Co., Ltd.'s (HKG:1643) Low P/E
Mar 25
We Think You Should Be Aware Of Some Concerning Factors In Modern Chinese Medicine Group's (HKG:1643) Earnings
Sep 02Calculating The Fair Value Of Modern Chinese Medicine Group Co., Ltd. (HKG:1643)
Jun 07Revenue & Expenses BreakdownBeta
How Modern Chinese Medicine Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 344 | 49 | 36 | 0 |
| 30 Sep 23 | 364 | 57 | 38 | 0 |
| 30 Jun 23 | 384 | 65 | 41 | 0 |
| 31 Mar 23 | 392 | 77 | 41 | 0 |
| 31 Dec 22 | 400 | 88 | 42 | 0 |
| 30 Sep 22 | 392 | 88 | 44 | 0 |
| 30 Jun 22 | 385 | 88 | 45 | 0 |
| 31 Mar 22 | 373 | 85 | 45 | 0 |
| 31 Dec 21 | 361 | 82 | 45 | 0 |
| 30 Sep 21 | 356 | 74 | 49 | 0 |
| 30 Jun 21 | 323 | 68 | 40 | 0 |
| 31 Mar 21 | 316 | 66 | 36 | 0 |
| 31 Dec 20 | 309 | 64 | 32 | 0 |
| 30 Sep 20 | 265 | 58 | 19 | 0 |
| 31 Dec 19 | 219 | 46 | 22 | 0 |
| 31 Dec 18 | 174 | 48 | 7 | 0 |
| 31 Dec 17 | 106 | 26 | 7 | 0 |
Quality Earnings: 1643 has high quality earnings.
Growing Profit Margin: 1643's current net profit margins (14.2%) are lower than last year (22%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1643's earnings have grown by 5.9% per year over the past 5 years.
Accelerating Growth: 1643's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1643 had negative earnings growth (-44.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.3%).
Return on Equity
High ROE: 1643's Return on Equity (10.3%) is considered low.